Showing 1951-1960 of 8649 results for "".
- FDA Approves Zeiss MEL 90 Excimer Laserhttps://modernod.com/news/fda-approves-zeiss-mel-90-excimer-laser/2482611/Zeiss has received FDA approval for the MEL 90, giving the excimer laser technology simultaneous approval for all three major indications: myopia, hyperopia, and mixed astigmatism. The Zeiss MEL 90 fully integrates into the company's Corneal Refractive Workflow,
- Bausch + Lomb Launches enVista Aspire Monofocal and Toric IOLs in the European Unionhttps://modernod.com/news/bausch-lomb-launches-envista-aspire-monofocal-and-toric-iols-in-the-european-union/2482610/Bausch + Lomb announced the commercial launch of the enVista Aspire monofocal and toric IOLs in the European Union after receiving a CE Mark late last year. According to B+L, enVista Aspire combines 'intermediate optimized' optics, which are designed for a broader dept
- Canyon Labs Acquire's iuvo BioScience’s Lab Services and Consulting Businesseshttps://modernod.com/news/canyon-labs-acquires-iuvo-biosciences-lab-services-and-consulting-businesses/2482600/Canyon Labs, a provider of analytical & packaging lab testing and consulting for medical devices and pharmaceuticals, has acquired the laboratory services and scientific consulting divisions of iuvo BioScience, a provider of ophthalmic medical device and pharmaceutical cli
- Konan Medical USA Launches objectiveFIELD Visual Field Analyzerhttps://modernod.com/news/konan-medical-usa-launches-objectivefield-visual-field-analyzer/2482534/Konan Medical USA announced the commercial launch of its objectiveFIELD (OFA) visual field analyzer. The OFA is an objective visual field analyzer designed to detect visual field abnormalities using pupillary responses. According to Konan Medical, unlike traditional subjectiv
- Alcon to Showcase Latest Innovations at AAO 2024 Annual Meetinghttps://modernod.com/news/alcon-to-showcase-latest-innovations-at-aao-2024-annual-meeting/2482489/Alcon will unveil its latest clinical data and product innovations at the American Academy of Ophthalmology (AAO) 2024 annual meeting. Attendees, including ophthalmologists, surgical staff, researchers, and industry leaders, are invited to visit Alcon at booth #4008 for hands-on demonstrations an
- Novaliq and Laboratoires Théa Announce EU Approval for Vevizye for Dry Eye Diseasehttps://modernod.com/news/novaliq-and-laboratoires-thea-announce-partnership-and-eu-approval-for-vevizye/2482466/Novaliq and Laboratoires Théa announced the European Commission’s approval of Vevizye (ciclosporin 0.1% eye drops solution) for the treatment of moderate to severe dry eye disease (DED) in adults unresponsive to tear substitutes. Vevizye is based on Nova
- Andreas Pecher to Succeed Dr. Karl Lamprecht as President and CEO of Carl Zeiss AGhttps://modernod.com/news/andreas-pecher-to-succeed-dr-karl-lamprecht-as-president-and-ceo-of-carl-zeiss-ag/2482461/After nearly two decades of leadership at Carl Zeiss AG, Karl Lamprecht, the current President and CEO, has announced that he will not be extending his contract, which is set to expire in the spring of 2025. Andreas Pecher was appointed the company's new President and CEO, effective Apri
- Aurion Biotech Launches Vyznova in Japan, the First Cell Therapy for Corneal Endothelial Diseasehttps://modernod.com/news/aurion-biotech-launches-vyznova-in-japan-the-first-cell-therapy-for-corneal-endothelial-disease/2482458/Aurion Biotech announced the commercial launch of Vyznova (neltependocel) in Japan. Vyznova is the first approved cell therapy for the treatment of the corneal endothelial disease, bullous keratopathy. The therapy has received both regulatory and reimbursement approval in Japa
- AAOF and Meta Reality Labs Launch $1.5 Million Open-Science Initiative to Study Myopia and Visual Experiencehttps://modernod.com/news/aaof-and-meta-reality-labs-launch-15-million-open-science-initiative-to-study-myopia-and-visual-experience/2482454/The American Academy of Optometry Foundation (AAOF) has partnered with Meta Reality Labs to fund an open-science research initiative aimed at understanding the relationship between visual experience and the onset and progression of myopia. This collaboration will support three independent researc
- Former Regenxbio Execs Announce Launch of Gene Therapy Company Tern Therapeuticshttps://modernod.com/news/former-regenxbio-execs-announce-launch-of-gene-therapy-company-turn-therapeutics/2482414/Tern Therapeutics announced its official launch alongside the successful closing of a $15 million financing round. Simultaneously, Tern revealed a global licensing agreement with Regenxbio to acquire two gene therapy programs—RGX-381 and RGX-181—now designated as TTX-381 and